

Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.



"While sales of analgesics are increasing, the market is still up against a few challenges. A high degree of brand loyalty makes it difficult to get consumers to try new brands. Alternatively, opportunities for innovation present new usage occasions to grow market sales." – Emily Krol, Health and Wellness Analyst

This report looks at the following areas:

- How can companies innovate in the analgesics category?
- What opportunities are there to increase external analgesic use?
- How will the aging population affect the OTC analgesic market?

Recent sales of OTC (over the counter) analgesics are boosted by several key brands returning to market. Additionally, there is a high need for remedies that treat pain, due to increased stress leading to headaches, intense exercise regimens leading to sore muscles, and high rates of arthritis among an aging population.

Despite that, there is still an overall concern about product ingredients, helping to boost the market of external remedies and alternative ways to treat pain. This report examines the future potential for analgesics, with a particular emphasis on product selection. Interest in product format, attributes, and purchase habits will be explored to provide insight into market trends.

BUY THIS REPORT NOW

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533

> Brazil 0800 095 9094

Americas +1 (312) 943 5250

арас +61 (0) 2 8284 8100

EMAIL: oxygen@mintel.com

DID YOU KNOW?

This report is part of a series of reports, produced to provide you with a more holistic view of this market



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Table of Contents

Scope and Themes

What you need to know Definition Data sources Sales data Consumer survey data Abbreviations and terms Abbreviations Terms

Executive Summary

Overview

The market

Figure 1: Total US sales and fan chart forecast of OTC analgesics, at current prices, 2009-19

Segment performance

Figure 2: Sales of OTC analgesics segmented by type, 2012 and 2014

Key players

Figure 3: MULO sales of OTC analgesics, by leading companies, rolling 52 weeks 2013 and 2014

The consumer

Product usage

Figure 4: OTC analgesic usage, by age, March 2014 Figure 5: Reasons used OTC analgesics, March 2014

Purchase habits

Figure 6: Purchase behaviors, March 2014

Ways to incite trial

Figure 7: Interest in product innovations, March 2014

What we think

Issues and Insights

How can companies innovate in the analgesics category? The issues The implications What opportunities are there to increase external analgesic use? The issues The implications How will the aging population affect the OTC analgesic market? The issues The implications

BUY THIS REPORT NOW

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMALL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

	Trend: FSTR HYPR
	Trend: Totophobia
	Trend: Prepare for the Worst
Ma	rket Size and Forecast
	Key points
	Key brands return to shelf helps to boost OTC analgesic sales
	Outlook for OTC analgesics positive
	Sales and forecast of OTC analgesics Figure 8: Total US sales and forecast of OTC analgesics, at current prices, 2009-19
	Figure 9: Total US sales and forecast of OTC analgesics, at inflation-adjusted prices, 2009-19
	Fan chart forecast Figure 10: Total US sales and fan chart forecast of OTC analgesics, at current prices, 2009-19
Ma	rket Drivers
	Key points
	Aging population increases need for pain relief Figure 11: Population by age, 2009-19
	Increased stress leads to headaches
	High rates of exercise bode well for pain treatment Figure 12: Regular exercise participation, by age, November 2012-December 2013
	Effects of the ACA on OTC analgesics
Со	mpetitive Context
	Key points
	Alternative ways to treat pain Figure 13: Ways to treat pain, by gender and age, March 2014
Se	gment Performance
	Key points
	Internal dominates market while external boasts strong growth rates Figure 14: Sales of OTC analgesics, segmented by type, 2012 and 2014
	Internal analgesics benefit from name brands returning to market Figure 15: Sales of OTC internal analgesics, by product form, 2009-14
	Figure 16: Total US sales and forecast of OTC internal analgesics, at current prices, 2009-19
	External analgesics experience uptick Figure 17: Sales of OTC external analgesics, by product form, 2009-14

Key points

BUY THIS REPORT NOW

VISEL: store.mintel.com CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMALL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Most analgesic sales at "other" retail channels Figure 19: #Targetrun print ad

Sales at drug stores slow

Potential for alternative shopping and delivery formats to rise

Sales of OTC analgesics, by channel

Figure 20: Total US retail sales of OTC analgesics, by channel, at current prices, 2009-14

Leading Companies

Key points

Brands coming back to shelf increases competition

Manufacturer sales of OTC analgesics

Figure 21: MULO sales of OTC analgesics, by leading companies, rolling 52 weeks 2013 and 2014

Manufacturer volume of select OTC analgesics

Figure 22: MULO sales and volume of select OTC internal analgesics, rolling 52 weeks 2013 and 2014

Brand Share – OTC Internal Analgesics

Key points

Brands returning to market boost internal analgesics, challenge private label

Despite new innovations and heaving marketing, Advil sales down

Manufacturer sales of OTC internal analgesics

Figure 23: MULO sales of OTC internal analgesics, by leading companies, rolling 52 weeks 2013 and 2014

Leading brands highly competitive

Figure 24: Key purchase measures for the top OTC internal analgesic brands, by household penetration, 52 weeks ending Dec. 30, 2012 (year ago) and Dec. 29, 2013 (current)

Advil and Tylenol top internal analgesic brand usage

Figure 25: Brands of headache and pain relievers used, by age, November 2012-December 2013

Brand Share - External Analgesics: Rubs

Key points

Icy Hot accounts for nearly a quarter of MULO sales

New introductions from Salonpas boosts category

Younger users driving segment

Manufacturer sales of external analgesic rubs

Figure 26: MULO sales of OTC external analgesic rubs, by leading companies, rolling 52 weeks 2013 and 2014

Icy Hot increases household penetration

Figure 27: Key purchase measures for the top OTC analgesic rubs brands, by household penetration, 52 weeks ending Dec. 30, 2012 (year ago) and Dec. 29, 2013 (current)

Icy Hot most used brand

Figure 28: Brands of nonprescription pain relieving rubs, liquids, and wraps, by age, November 2012-December 2013

Brand Share - External Analgesics - Heat/Ice Packs

Key points

Heat/ice pack sales remain flat

Opportunity to increase sales for ThermaCare

BUY THIS REPORT NOW

VISIT: store.mintel.com CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMAIL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Manufacturer sales of heat/ice packs

Figure 29: MULO sales of heat/ice packs, by leading companies, rolling 52 weeks 2013 and 2014

Household penetration for ThermaCare declines along with sales

Figure 30: Key purchase measures for the top OTC external analgesic heat/ice packs, by household penetration, 52 weeks ending Dec. 30, 2012 (year ago) and Dec. 29, 2013 (current)

Innovations and Innovators

Overall introductions decline

Figure 31: Pain relief product launches, by subcategory, 2008-14

Internal pain relievers aim to relieve pain fast

Figure 32: Share of branded/private label ingested pain relief product launches, 2008-14

Noningested pain relievers promise to work fast, last long

Alternative formats appeal to external users

Marketing Strategies

Overview of the brand landscape

Doing good to feel good

Sports-related pain

Figure 33: Tough Mudder promotion

Relieving pain fast

Figure 34: Excedrin, fast fixes for your home and office

Getting back to normal

Social Media

Key points

Market overview

Key social media metrics

Figure 35: Key performance indicators, selected analgesic brands, April 21, 2013-April 20, 2014

Brand usage and awareness

Figure 36: Brand usage and awareness of analgesic brands, March 2014

Interaction with brands

Figure 37: Interaction with analgesic brands, March 2014

Leading Online Campaigns

Online games and contests

Celebrity endorsements

What we think

Online conversations

Figure 38: Online mentions, selected analgesic brands, May 5, 2013-May 4, 2014

Where are people talking about analgesic brands?

Figure 39: Mentions by page type, selected analgesic brands, May 5, 2013-May 4, 2014

What are people talking about online?

Figure 40: Mentions by topic of conversation, selected analgesic brands, May 5, 2013-May 4, 2014

BUY THIS REPORT NOW

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMALL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Product Usage

Key points

Internal analgesic use most common, opportunities to expand external Figure 41: OTC analgesic usage, by age, March 2014

Frequency of internal analgesic use increases with age

Figure 42: Frequency of headache and pain reliever use, by age, November 2012-December 2013

Opportunity to promote liquid shots to younger men

External users more likely to use both internal and external

Figure 43: OTC analgesic usage, by OTC analgesic usage, March 2014

Reasons for Using

Key points

OTC analgesic usage depends on pain type

Figure 44: Reasons used OTC analgesics, March 2014

Headaches and migraines prevalent among younger users

Opportunity to target menstrual pain relief

Aging population requires specific treatments

Figure 45: Reasons used OTC internal analgesics, by age, March 2014

Purchasing Habits

Key points

High brand loyalty among internal and external users

Figure 46: Purchase behaviors, March 2014

Older users brand loyal

Figure 47: Tylenol print ad

Acetaminophen concerns drive consumer education

Figure 48: Tylenol warning label

Younger users need a little more guidance

Figure 49: OTC analgesic purchase behaviors, by age, March 2014

Areas for Innovation

Key points

Working fast would influence most users to trial

Figure 50: Interest in product innovations, by age, March 2014

Despite brand loyalty, external users could be enticed to switch

Create more female-friendly external remedies

Figure 51: Interest in product innovations, March 2014

Product Format

Key points

Convenience drives product format interest

Figure 52: Usage of and interest in product formats, March 2014

BUY THIS REPORT NOW

VISIT: store.mintel.com CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMAIL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Younger users prefer more on the go, convenient formats

Figure 53: Usage of product formats, by age, March 201

External formats can appeal to both internal and external users

Figure 54: Interest in trying product formats, by OTC analgesic usage, March 2014

Race and Hispanic Origin

Key points

Product usage differs from general population

Figure 55: OTC analgesic usage, by race/Hispanic origin, March 2014

Product claims could incite trial

Figure 56: Interest in product innovations, by race/Hispanic origin, March 2014

Black users brand loyal

Education still needed among Hispanics

Figure 57: OTC analgesic purchase behaviors, race/Hispanic origin, March 2014

Appendix – Other Market Tables

Demographics

Figure 58: Population by age, 2009-19

Retail channels

Figure 59: Total US retail sales of OTC analgesics, by channel, at current prices, 2012 and 2014

Innovations and innovators

Figure 60: Ingested pain relief product launches, top claims, 2008-14

Figure 61: Noningested pain relief product launches, top claims, 2008-14

Appendix - Other Useful Consumer Tables

Brand usage – internal

Figure 62: Brands of headache and pain relievers used, by race/Hispanic origin, November 2012-December 2013

Figure 63: Brands of headache and pain relievers used, by gender and age, November 2012-December 2013

Brand usage - external

Figure 64: Brands of nonprescription pain relieving rubs, liquids and wraps, October 2007-December 2013

Figure 65: Brands of nonprescription pain relieving rubs, liquids and wraps, by gender and age, November 2012-December 2013

Reasons for using

Figure 66: Reasons used OTC analgesics, March 2014

Figure 67: Reasons used OTC internal analgesics, by gender and age, March 2014

Product usage

Figure 68: OTC analgesic usage, by gender, March 2014

Figure 69: OTC analgesic usage, by gender and age, March 2014

Figure 70: OTC analgesic usage, by brand users, March 2014

Ingredients

Figure 71: Types of OTC internal analgesics used, by gender and age, March 2014

Types of pain/reasons for using

BUY THIS REPORT NOW

VISIT: store.mintel.com CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMAIL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Figure 72: Reasons used OTC analgesics, March 2014

Figure 73: Reasons used OTC internal analgesics, by gender and age, March 2014

Figure 74: Reasons used OTC analgesics – Any OTC external analgesic users, by gender and age, March 2014

Treating pain

Figure 75: Ways to treat pain, by OTC analgesic usage, March 2014

Figure 76: Ways to treat pain, by race/Hispanic origin, March 2014

Purchasing habits

Figure 77: Purchase behaviors, March 2014

Areas for innovation

Figure 78: Interest in product innovations, by purchase behaviors - Any OTC internal analgesic users, March 2014 (part 1)

Figure 79: Interest in product innovations, by purchase behaviors – Any OTC internal analgesic users, March 2014 (part 2)

Figure 80: Interest in product innovations, by gender and age, March 2014

Product format

Figure 81: Interest in product innovations - Have not used, but interested in trying, by gender and age, March 2014

Appendix - Social Media

Brand analysis

Figure 82: Advil key social media indicators, May 2014

Figure 83: Tylenol key social media indicators, May 2014

Figure 84: Aleve key social media indicators, May 2014

Figure 85: Excedrin key social media indicators, May 2014

Figure 86: Bayer key social media indicators, May 2014

Brand usage or awareness

Figure 87: Brand usage or awareness, March 2014

Figure 88: Tylenol usage or awareness, by demographics, March 2014

Figure 89: Advil usage or awareness, by demographics, March 2014

Figure 90: Bayer usage or awareness, by demographics, March 2014

Figure 91: Motrin usage or awareness, by demographics, March 2014

- Figure 92: Excedrin usage or awareness, by demographics, March 2014
- Figure 93: Aleve usage or awareness, by demographics, March 2014

Activities done

Figure 94: Activities done, March 2014

Figure 95: Tylenol – Activities done – I have looked up/talked about this brand online on social media, by demographics, March 2014 Figure 96: Tylenol – Activities done – I have contacted/interacted with the brand online on social media to..., by demographics, March 2014 Figure 97: Tylenol – Activities done – I follow/like the brand on social media because..., by demographics, March 2014 Figure 98: Tylenol – Activities done – I have researched the brand on social media to..., by demographics, March 2014 Figure 99: Advil – Activities done – I have looked up/talked about this brand online on social media..., by demographics, March 2014 Figure 100: Advil – Activities done – I have contacted/interacted with the brand online on social media to..., by demographics, March 2014 Figure 100: Advil – Activities done – I have contacted/interacted with the brand online on social media to..., by demographics, March 2014 Figure 101: Advil – Activities done – I follow/like the brand on social media because..., by demographics, March 2014 Figure 102: Advil – Activities done – I have researched the brand on social media because..., by demographics, March 2014

BUY THIS REPORT NOW

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMALL: oxygen@mintel.com



Report Price: £2466.89 | \$3995.00 | €3133.71

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

	Figure 103: Bayer – Activities done – I have looked up/talked about this brand online on social media, by demographics, March 2014
	Figure 104: Bayer – Activities done – I have contacted/interacted with the brand online on social media to, by demographics, March 2014
	Figure 105: Bayer – Activities done – I have researched the brand on social media to, by demographics, March 2014
	Figure 106: Motrin – Activities done – I have looked up/talked about this brand online on social media, by demographics, March 2014
	Figure 107: Motrin – Activities done – I have contacted/interacted with the brand online on social media to, by demographics, March 2014
	Figure 108: Motrin – Activities done – I have researched the brand on social media to, by demographics, March 2014
	Figure 109: Excedrin – Activities done – I have looked up/talked about this brand online on social media, by demographics, March 2014
	Figure 110: Excedrin – Activities done – I have contacted/interacted with the brand online on social media to, by demographics, March 2014
	Figure 111: Excedrin – Activities done – I have researched the brand on social media to, by demographics, March 2014
	Figure 112: Aleve – Activities done – I have looked up/talked about this brand online on social media, by demographics, March 2014
	Figure 113: Aleve – Activities done – I have contacted/interacted with the brand online on social media to, by demographics, March 2014
	Figure 114: Aleve – Activities done – I have researched the brand on social media to, by demographics, March 2014

Appendix – Information Resources Inc. Builders Panel Data Definitions

Information Resources Inc. Consumer Network Metrics

Appendix – Trade Associations

BUY THIS REPORT NOW

VISIT: store.mintel.com CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094 Americas +1 (312) 943 5250 | APAC +61 (0) 2 8284 8100 EMALL: oxygen@mintel.com